Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Arch Biochem Biophys ; 730: 109425, 2022 11 15.
Article in English | MEDLINE | ID: mdl-36198346

ABSTRACT

Radiotherapy acts by damaging DNA and hindering cancer cell proliferation. H2AX is phosphorylated to produce γH2AX that accumulates in a response to DNA double-strand breaks. Non-coding RNA can influence DNA damage response and enhance DNA repair, which show potential for cancer treatment. The study aimed to observe the influence of SPI1 on the radiosensitivity of lung squamous cell carcinoma (LUSC) and to investigate the mechanisms. SPI1, TPX2, and RNF2 were overexpressed in LUSC tissues and radioresistant cells comspared with adjacent tissues and parental cells, respectively. The binding between SPI1 and TPX2 or RNF2 promoter was investigated using ChIP-qPCR and dual-luciferase assays. SPI1 bound to TPX2 and RNF2 promoters and activated their transcription. SPI1 downregulation increased the radiosensitivity of LUSC cells, which was compromised by TPX2 or RNF2 overexpression. Meanwhile, SPI1 downregulation elevated the protein expression of γH2AX at the late stage of DNA damage response and suppressed DNA damage repair in LUSC cells, which were compromised by TPX2 or RNF2. These results indicate that SPI1 silencing potentiates radiosensitivity in LUSC cells by downregulating the transcription of TPX2 and RNF2, which provides a potential target for the radiotherapy in LUSC.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Lung Neoplasms , Humans , Transcriptional Activation , Carcinoma, Non-Small-Cell Lung/genetics , Radiation Tolerance/genetics , Carcinoma, Squamous Cell/pathology , Cell Proliferation/genetics , Lung Neoplasms/genetics , Lung Neoplasms/radiotherapy , Lung Neoplasms/pathology , RNA, Untranslated , Lung/metabolism , Gene Expression Regulation, Neoplastic , Cell Line, Tumor , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/metabolism , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Polycomb Repressive Complex 1/genetics , Polycomb Repressive Complex 1/metabolism
2.
Nutr Cancer ; 74(6): 2095-2104, 2022.
Article in English | MEDLINE | ID: mdl-34643463

ABSTRACT

BACKGROUND: The preoperative prognostic nutritional index (PNI) is associated with postoperative complications and long-term survival of various cancers. However, its role in esophageal squamous cell carcinoma (ESCC) is inconclusive. The aim of this study was to identify the prognostic value of PNI in predicting survival in ESCC patients undergoing radical radiotherapy. METHODS: We retrospectively reviewed 354 ESCC patients undergoing radical radiotherapy. The time-dependent receiver operating characteristics was used to determine the optimal cutoff value. The association between PNI and survival was determined by Kaplan-Meier method and Cox regression model. Propensity score matching was applied to balance the baseline characteristics. RESULTS: PNI was positively correlated with hemoglobin (P < 0.001) and prealbumin (P < 0.001). The optimal cutoff value of PNI was set at 50.5. The 5-year overall survival (OS) in low PNI group and high PNI group were 20.8% and 34.0%, respectively (P < 0.001). The 5-year progression free survival in patients with low PNI and high PNI were 15.2% and 28.5%, respectively (P = 0.001). Multivariate analysis showed that PNI was a significant predictor for OS (P = 0.038). In the PSM analysis, PNI still remained an independent predictor for OS (P = 0.015). CONCLUSIONS: The PNI is a significant and independent predictor for OS of ESCC patients undergoing radical radiotherapy.


Subject(s)
Esophageal Neoplasms , Esophageal Squamous Cell Carcinoma , Esophageal Squamous Cell Carcinoma/radiotherapy , Humans , Nutrition Assessment , Prognosis , Propensity Score , Retrospective Studies
3.
Invest New Drugs ; 39(3): 764-774, 2021 06.
Article in English | MEDLINE | ID: mdl-33245464

ABSTRACT

Anaplastic thyroid cancer (ATC) is a rare type of thyroid cancer (TC) with no effective therapeutic strategy. Although surgery, chemotherapy and radiation are all available for ATC treatment, the median survival for ATC patients is less than 6 months. In this study, we aimed to study on resistant mechanisms to B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitor and identify effective combinational therapy for ATC patients. TC cells were treated with Vemurafenib and cell apoptosis and viability were analyzed by flow cytometry and MTT assay. Monolayer and sphere cells were isolated from ATC cells to detect the mRNA level of stem cell markers and differentiation markers by RT-PCR. Phosphor-STAT3 level in sphere and monolayer cells was tested by Western blotting. The xenotransplantation animal model has established to analyze the anti-tumor effect of Vemurafenib and Stattic combinational therapy. Undifferentiated TC cells were resistant to Vemurafenib treatment. Sphere cells isolated from ATC showed no significant change in cell viability and apoptosis upon Vemurafenib treatment, and expressed a high level of stem cell marker and phosphor-STAT3. STAT3 inhibition enhanced the tumorigenic capacity and increased Vemurafenib sensitivity in ATC cell lines. Stattic significantly enhanced anti-tumor effect of Vemurafenib in mouse model. Our findings demonstrate that the combinational therapy of Vemurafenib and Stattic is an effective therapeutic treatment for ATC patients.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclic S-Oxides/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , STAT3 Transcription Factor/antagonists & inhibitors , Thyroid Carcinoma, Anaplastic/drug therapy , Thyroid Neoplasms/drug therapy , Vemurafenib/therapeutic use , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Cyclic S-Oxides/pharmacology , Drug Resistance, Neoplasm/drug effects , Drug Synergism , Female , Humans , Mice, Nude , STAT3 Transcription Factor/metabolism , Thyroid Carcinoma, Anaplastic/metabolism , Thyroid Carcinoma, Anaplastic/pathology , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology , Tumor Burden/drug effects , Vemurafenib/pharmacology
4.
Hu Li Za Zhi ; 65(1): 61-69, 2018 Feb.
Article in Zh | MEDLINE | ID: mdl-29405021

ABSTRACT

BACKGROUND: Chemotherapy may induce peripheral neuropathy, which often results in the chemotherapy dose being reduced or the chemotherapy regimen being stopped. At present, there are no treatment guidelines for chemotherapy-induced peripheral neuropathy. Glutamine is one of the treatment strategies currently applied in practice. This strategy is expensive and lacks clear evidence as to its efficacy. PURPOSE: To evaluate the effect of oral glutamine on CIPN in cancer patients. METHODS: PICO (population- intervention- comparison- outcome) was used to focus the problem: P: cancer patient; I: glutamine, L-glutamine; C: usual care; O: alleviate, reduce, improve, and prevent. Databases searched included Airiti Library, Cochrane Library, CINAHL, and PubMed. Three randomized clinical trials and two quasi-experimental designs were evaluated using evidence-based appraisal. RESULTS: Four studies used 30 g/day of glutamine either at the beginning of chemotherapy or at 24 hours after the beginning of chemotherapy. The shortest duration for taking glutamine was four days and longest duration was two months. The incidences of CIPN-induced pain were significantly different (risk ratio = 0.26; 95% CI [0.09, 0.70], Z = 2.65, p = .008) between the intervention and control groups. The incidences of CIPN grading, numbness, and muscle weakness were not significantly different between the intervention and control groups. From an economic point of view, the clinical efficacy of taking glutamine does not justify the additional daily cost to the patient of NT¤500 (about US¤17). CONCLUSIONS / IMPLICATIONS FOR PRACTICE: Because of the small sample size, minimal effects of glutamine, and no significant decrease in risk, we do not suggest routinely using oral glutamine to prevent or reduce CIPN symptoms in cancer patients.


Subject(s)
Antineoplastic Agents/adverse effects , Glutamine/administration & dosage , Neoplasms/drug therapy , Peripheral Nervous System Diseases/drug therapy , Administration, Oral , Evidence-Based Nursing , Humans , Peripheral Nervous System Diseases/chemically induced
5.
J Gen Virol ; 96(Pt 3): 637-649, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25502647

ABSTRACT

Marek's disease virus (MDV) is an important oncogenic alphaherpesvirus that induces rapid-onset T-cell lymphomas in its natural hosts. The Meq-clustered miRNAs encoded by MDV have been suggested to play potentially critical roles in the induction of lymphomas. Using the technique of bacterial artificial chromosome mutagenesis, we have presently constructed a series of specific miRNA-deleted mutants and demonstrate that these miRNAs are not essential for replication of MDV and have no effects on the early cytolytic or latent phases of the developing disease. However, compared to the parental GX0101, mortality of birds infected with the mutants GXΔmiR-M2, GXΔmiR-M3, GXΔmiR-M5, GXΔmiR-M9 and GXΔmiR-M12 was reduced from 100 % to 18 %, 30 %, 48 %, 24 % and 14 %, coupled with gross tumour incidence reduction from 28 % to 8 %, 4 %, 12 %, 8 % and 0 %, respectively. Our data confirm that except for mdv1-miR-M4, the other Meq-clustered miRNAs also play critical roles in MDV oncogenesis. Further work will be needed to elucidate the miRNA-mediated regulatory mechanisms that trigger the development of MD lymphomas.


Subject(s)
Carcinogenesis , Gene Expression Regulation, Viral , Herpesvirus 2, Gallid/metabolism , MicroRNAs/metabolism , Poultry Diseases/virology , Animals , Chickens , Herpesvirus 2, Gallid/genetics , Lymphoma/veterinary , Lymphoma/virology , Marek Disease/pathology , Marek Disease/virology , MicroRNAs/genetics , Poultry Diseases/pathology , RNA, Viral/genetics , RNA, Viral/metabolism
6.
Virus Genes ; 50(2): 245-52, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25666057

ABSTRACT

In the past decade, a large number of microRNAs (miRNAs) have been identified in the viral genome of Gallid herpesvirus 2 (GaHV-2), which is historically known as Marek's disease virus type 1. The biological role of most GaHV-2 miRNAs remains unclear. In the present study, we have performed an overall gene expression profile of GaHV-2 miRNAs during the virus life cycle at each phase of the developing disease, a highly contagious, lymphoproliferative disorder, and neoplastic immunosuppressive disease of poultry known as the Marek's disease. According to their distinct in vivo expression patterns, the GaHV-2 miRNAs can be divided into three groups: 12 miRNAs in group I, including miR-M4-5p, displayed a typical expression pattern potentially correlated to the latent, late cytolytic, and/or the proliferative phases in the cycle of GaHV-2 pathogenesis; group II consisting of another 12 miRNAs with expression correlated to the early cytolytic and/or latent phases in GaHV-2's life cycle; while the other two miRNAs in group III showed no identical expression features. Our findings may provide meaningful clues in the search for further potential functions of viral miRNAs in GaHV-2 biology.


Subject(s)
Herpesvirus 2, Gallid/genetics , Lymphoma/veterinary , Marek Disease/virology , MicroRNAs/genetics , Poultry Diseases/virology , RNA, Viral/genetics , Animals , Chickens , Gene Expression Regulation, Viral , Herpesvirus 2, Gallid/physiology , Lymphoma/virology , MicroRNAs/metabolism , RNA, Viral/metabolism , Transcriptome
7.
Opt Lett ; 39(7): 2210-3, 2014 Apr 01.
Article in English | MEDLINE | ID: mdl-24686713

ABSTRACT

We demonstrate a common-path tomographic diffractive microscopy technique for three-dimensional (3D) refractive-index (RI) imaging of unstained living cells. A diffraction grating is utilized to generate a reference beam that traverses a blank region of the sample in a common-path off-axis interferometry setup. Single-shot phase images captured at multiple illumination angles are used for 3D RI reconstruction based on optical diffraction tomography. The common-path configuration shows lower temporal phase fluctuations and better RI resolution than a Mach-Zehnder configuration. 3D subcellular RI distributions of live HeLa cells are quantified.


Subject(s)
Microscopy/methods , Tomography/methods , Cell Survival , HeLa Cells , Humans , Imaging, Three-Dimensional , Polystyrenes/chemistry , Refractometry
8.
Am J Ther ; 21(5): 371-6, 2014.
Article in English | MEDLINE | ID: mdl-22975663

ABSTRACT

In this study, we evaluated the effect of chemotherapy (CT) and thoracic radiotherapy (RT) integration and the timing of RT on survival of elderly patients with limited-stage small-cell lung cancer. Eighty patients were retrospectively analyzed. All the patients revived thoracic RT and 70 patients received ≥2 cycles of CT. Twenty-two patients received RT sequentially to CT, 19 with RT consolidated with CT, and 29 with RT concurrent with CT. Early chest irradiation was defined as beginning RT after 1-3 cycles of CT (n = 44), and late chest irradiation was defined as occurring after ≥4 cycles of CT (n = 26). Twenty-six patients (32.5%) achieved complete response, 37 (46.2%) partial response, 10 (12.5%) stable disease, and 7 (8.7%) progressive disease. The median survival time for all patients was 19 months. The 1-, 2-, and 3-year overall survival (OS) rates were 68.9%, 41.3%, and 31.7%, respectively. In univariate analyses, the volume of the primary tumor, CT, treatment modality, timing of RT, target volume, and RT dose were significantly associated with OS. At 3 years, concomitant chemoradiotherapy was superior to consolidated and sequential chemoradiotherapy (40.0% vs. 36.9% vs. 40.0%, respectively). The rate of OS at 3 years was 37.1% for patients receiving early-RT and 27.8% for those receiving late-RT (P = 0.006). Multivariate analysis showed that CT and RT dose were independent factors influencing OS. Concurrent chemoradiotherapy resulted in a high survival rate. A radiation dose-response relationship was observed, and a dose of at least 60-Gy daily radiation demonstrated improved survival.


Subject(s)
Chemoradiotherapy , Lung Neoplasms/therapy , Small Cell Lung Carcinoma/therapy , Aged , Chemoradiotherapy/adverse effects , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Radiotherapy Dosage , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/pathology
9.
Virus Genes ; 47(2): 282-91, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23813248

ABSTRACT

Marek's disease is a highly contagious, oncogenic, and immunosuppressive avian viral disease. Surveillance of newly registered Marek's disease virus (MDV) isolates is meaningful for revealing the potential factors involved in increased virulence. Presently, we have focused on the molecular characteristics of all available MDVs from China, including 17 new Henan isolates. Based on Meq, gE, and gI genes, we found that most Chinese isolates contain conserved amino acid point mutations in Meq, such as E(77), A(115), A(139), R(176), and A(217), compared to USA virulent MDVs. However, the 59-aa or 60-aa insertions are only found in a few mild MDVs rather than virulent MDVs in China. Further phylogenetic analysis has demonstrated that a different genotype of MDV has been prevalent in China, and for virulent MDVs, their recent evolution has possibly been geographically restricted. Our study has provided more detailed information regarding the field MDVs circulating in China.


Subject(s)
Mardivirus/genetics , Mardivirus/isolation & purification , Marek Disease/virology , Animals , Chickens , China , Cluster Analysis , DNA, Viral/chemistry , DNA, Viral/genetics , Evolution, Molecular , Mardivirus/classification , Molecular Sequence Data , Mutation, Missense , Phylogeny , Point Mutation , Sequence Analysis, DNA , Viral Proteins/genetics
10.
J Air Waste Manag Assoc ; 63(10): 1190-8, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24282971

ABSTRACT

Mitigation of bioaerosol emissions from concentrated animal feeding operations (CAFOs) demands knowledge of bioaerosol concentrations feeding into an end-of-pipe air treatment process. The aim of this preliminary study was to measure total endotoxin and (1 --> 3)-beta-glucan concentrations at the air exhaust of 18 commercial CAFOs and to examine their variability with animal operation type (swine farrowing, swine gestation, swine weaning, swine finishing, manure belt laying hen, and tom turkey) and season (cold, mild, and hot). The measured airborne concentrations of total endotoxin ranged from 98 to 23,157 endotoxin units (EU)/m3, and the airborne concentrations of total (1 --> 3)-beta-D-glucan ranged from 2.4 to 537.9 ng/m3. Animal operation type in this study had a significant effect on airborne concentrations of total endotoxin and (1 --> 3)-beta-D-glucan but no significant effect on their concentrations in total suspended particulate (TSP). Both endotoxin and (1 --> 3)-beta-D-glucan attained their highest airborne concentrations in visited tom turkey buildings. Comparatively, season had no significant effect on airborne concentrations of total endotoxin or (1 --> 3)-beta-D-glucan. Endotoxin and (1 --> 3)-beta-glucan concentrations in TSP dust appeared to increase as the weather became warmer, and this seasonal effect was significant in swine buildings. Elevated indoor temperatures in the hot season were considered to facilitate the growth and propagation of bacteria and fungi, thus leading to higher biocomponent concentrations in TSP.


Subject(s)
Air Pollutants/chemistry , Animal Husbandry , Endotoxins/chemistry , Housing, Animal , beta-Glucans/chemistry , Animals , Proteoglycans
11.
Zhonghua Zhong Liu Za Zhi ; 35(1): 45-9, 2013 Jan.
Article in Zh | MEDLINE | ID: mdl-23648300

ABSTRACT

OBJECTIVE: To investigate the predictive value of low dose volume of the lung on acute radiation pneumonitis (RP) in patients with esophageal cancer treated with three-dimensional conformal radiotherapy (3D-CRT) only, and to analyze the relation of comprehensive parameters of the dose-volume V5, V20 and mean lung dose (MLD) with acute RP. METHODS: Two hundred and twenty-two patients with esophageal cancer treated by 3D-CRT have been followed up. The V5-V30 and MLD were calculated from the dose-volume histogram system. The clinical factors and treatment parameters were collected and analyzed. The acute RP was evaluated according to the RTOG toxicity criteria. RESULTS: The acute RP of grade 1, 2, 3 and 4 were observed in 68 (30.6%), 40 (18.0%), 8 (3.6%) and 1 (0.5%) cases, respectively. The univariate analysis of measurement data:The primary tumor length, radiation fields, MLD and lung V5-V30 had a significant relationship with the acute RP. The magnitude of the number of radiation fields, the volume of GTV, MLD and Lung V5-V30 had a significant difference in whether the ≥ grade 1 and ≥ grade 2 acute RP developed or not. Binary logistic regression analysis showed that MLD, Lung V5, V20 and V25 were independent risk factors of ≥ grade 1 acute RP, and the radiation fields, MLD and Lung V5 were independent risk factors of ≥ grade 2 acute RP. The ≥ grade 1 and ≥ grade 2 acute RP were significantly decreased when MLD less than 14 Gy, V5 and V20 were less than 60% and 28%,respectively. When the V20 ≤ 28%, the acute RP was significantly decreased in V5 ≤ 60% group. When the MLD was ≤ 14 Gy, the ≥ 1 grade acute RP was significantly decreased in the V5 ≤ 60% group. When the MLD was >14 Gy, the ≥ grade 2 acute RP was significantly decreased in the V5 ≤ 60% group. CONCLUSIONS: The low dose volume of the lung is effective in predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-CRT only. The comprehensive parameters combined with V5, V20 and MLD may increase the effect in predicting radiation pneumonitis.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Esophageal Neoplasms/radiotherapy , Lung/radiation effects , Radiation Pneumonitis/etiology , Radiotherapy, Conformal/adverse effects , Acute Disease , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Radiation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Radiation Pneumonitis/pathology , Radiotherapy Dosage , Retrospective Studies
12.
J Thorac Dis ; 15(3): 1426-1432, 2023 Mar 31.
Article in English | MEDLINE | ID: mdl-37065550

ABSTRACT

Background: Surgery is commonly used to treat stage I lung cancer patients, whereas radiotherapy is applied to treat stage III lung cancer patients. However, few advanced-stage lung cancer patients benefit from surgery. This study aimed to investigate the efficacy of surgery for stage III-N2 non-small cell lung cancer (NSCLC) patients. Methods: A total of 204 patients with stage III-N2 NSCLC were included and divided into surgery (n=60) and radiotherapy (n=144) groups. The clinical characteristics [tumor node metastasis (TNM) stage, and adjuvant chemotherapy] and basic information (gender, age, and smoking/family history) of the included patients were evaluated. Furthermore, the patients' Eastern Cooperative Oncology Group (ECOG) scores and comorbidities were also evaluated, and the Kaplan-Meier approach was utilized to analyze their overall survival (OS). A multivariate Cox proportional hazards model was generated to analyze OS. Results: There was a significant difference in disease stages (IIIa and IIIb) between the surgery and radiotherapy groups (P<0.001). Compared with the surgery group, there were more patients with ECOG scores of 1 and 2 and fewer patients with ECOG scores of 0 in the radiotherapy group (P<0.001). Moreover, there was a significant difference in comorbidities between the stage III-N2 NSCLC patients in the two groups (P=0.011). The OS rate was higher significantly in stage III-N2 NSCLC patients in the surgery group compared to that in the radiotherapy group (P<0.05). Kaplan-Meier analysis demonstrated that the OS of III-N2 NSCLC was markedly better in the surgery group compared to the radiotherapy group (P<0.05). The multivariate proportional hazards model showed that age, T stage, surgery, disease stage, and adjuvant chemotherapy were independent prognostic predictors for OS in stage III-N2 NSCLC patients. Conclusions: Surgery is associated with improved OS in stage III-N2 NSCLC patients and is recommended to treat these patients.

13.
ACS Omega ; 8(47): 44689-44697, 2023 Nov 28.
Article in English | MEDLINE | ID: mdl-38046337

ABSTRACT

Preparing high-performance electrode materials from metal-organic framework precursors is currently a hot research topic in the field of energy storage materials. Improving the conductivity of such electrode materials and further increasing their specific capacitance are key issues that must be addressed. In this work, we prepared phosphoric acid-functionalized UiO-66 material as a precursor for carbonization, and after carbonization, it was combined with activated carbon to obtain nitrogen-/phosphorus-codoped carbonized UiO-66 composite material (N/P-C-UiO-66@AC). This material exhibits excellent conductivity. In addition, the carbonized product ZrO2 and the nitrogen-/phosphorus-codoped structure evidently improve the pseudocapacitance of the material. Electrochemical test results show that the material has a good electrochemical performance. The specific capacitance of the supercapacitor made from this material at 1.0 A/g is 140 F/g. After 5000 charge-discharge cycles at 10 A/g, its specific capacitance still remains at 88.5%, indicating that the composite material has good cycling stability. The symmetric supercapacitor assembled with this electrode material also has a high energy density of 11.0 W h/kg and a power density of 600 W/kg.

14.
Onkologie ; 35(6): 362-7, 2012.
Article in English | MEDLINE | ID: mdl-22722457

ABSTRACT

BACKGROUND: Chemotherapy (CT) in combination with thoracic radiotherapy (RT) can improve the survival of patients with limited-stage small cell lung cancer (LSSCLC). In the current study, we evaluated the prognostic factors, especially the effect of the therapy integration and the timing of RT, on survival. PATIENTS AND METHODS: We retrospectively studied 142 patients with LS-SCLC. All patients received thoracic RT and 126 patients received at least 2 cycles of CT; 38 patients received RT following CT cycles, 32 received RT between CT cycles, and 56 received RT concurrently with CT. RESULTS: For all patients, the 1-, 3-, and 4-year overall survival (OS) rates were 68.3, 31.2, and 28.6%, respectively. In univariate analyses, the volume of the primary tumor, T classification, CT, the target volume, the RT dose, and the treatment response were significantly associated with OS. The multivariate analysis showed that CT, the timing of RT, and RT dose were independent factors influencing the OS. CONCLUSION: Concurrent chemoradiotherapy could result in high survival rates, and early integration of thoracic RT was associated with a better outcome. A radiation dose-response relationship was observed in our study.


Subject(s)
Chemoradiotherapy/mortality , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/therapy , Adult , Aged , Female , Germany/epidemiology , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Prevalence , Prognosis , Retrospective Studies , Risk Factors , Small Cell Lung Carcinoma/pathology , Survival Analysis , Survival Rate , Treatment Outcome
15.
Acta Med Okayama ; 66(5): 399-407, 2012.
Article in English | MEDLINE | ID: mdl-23093058

ABSTRACT

Hypoxia-inducible factor-1α (HIF-1α) has been found to enhance tumor invasion and metastasis, but no study has reported its action in esophageal carcinoma. The goal of this study was to explore the probable mechanism of HIF-1α in the invasion and metastasis of esophageal carcinoma Eca109 cells in vitro and in vivo. mRNA and protein expression of HIF-1α, E-cadherin and matrix metalloproteinase-2 (MMP-2) under hypoxia were detected by RT-PCR and Western blotting. The effects of silencing HIF-1α on E-cadherin, MMP-2 mRNA and protein expression under hypoxia or normoxia were detected by RT-PCR and Western blotting, respectively. The invasive ability of Eca109 cells was tested using a transwell chambers. We established an Eca109-implanted tumor model and observed tumor growth and lymph node metastasis. The expression of HIF-1α, E-cadherin and MMP-2 in xenograft tumors was detected by Western blotting. After exposure to hypoxia, HIF-1α protein was up-regulated, both mRNA and protein levels of E-cadherin were down-regulated and MMP-2 was up-regulated, while HIF-1α mRNA showed no significant change. SiRNA could block HIF-1α effectively, increase E-cadherin expression and inhibit MMP-2 expression. The number of invading cells decreased after HIF-1α was silenced. Meanwhile, the tumor volume was much smaller, and the metastatic rate of lymph nodes and the positive rate were lower in vivo. Our observations suggest that HIF-1α inhibition might be an effective strategy to weaken invasion and metastasis in the esophageal carcinoma Eca109 cell line.


Subject(s)
Cadherins/antagonists & inhibitors , Esophageal Neoplasms/pathology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Matrix Metalloproteinase 2/genetics , Animals , Cadherins/genetics , Cell Line, Tumor , Female , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Mice , Neoplasm Invasiveness , Neoplasm Metastasis , Snail Family Transcription Factors , Transcription Factors/physiology
16.
Zhonghua Zhong Liu Za Zhi ; 34(4): 281-6, 2012 Apr.
Article in Zh | MEDLINE | ID: mdl-22781041

ABSTRACT

OBJECTIVE: To explore factors affecting the survival in patients after radical resection of esophageal carcinoma, and to provide a valuable reference for selecting treatment protocol after surgery. METHODS: Clinicopathological data of 618 esophageal cancer patients who underwent radical resection at the Fourth Hospital of Hebei Medical University from May 2002 to June 2006 were collected and reviewed in this study. All patients had no cancer history, did not receive preoperative radiotherapy or chemotherapy, and had Karnofsky performance scores ≥ 70. Univariate analysis was performed by using log-rank test to determine predictors of survival, and multivariable analysis was performed by a Cox regression model. RESULTS: The overall 1-, 3-, 5-year survival rates were 83.32%, 53.33%, 36.02%, respectively, and the median survival time was 38.33 months. The Cox regression analysis showed that operation mode, intraoperative findings of the extent of tumor invasion, pathological T stage, and the number of metastatic lymph nodes were significant predictors of survival. For patients with lymph node metastasis, the overall 1-, 3-, and 5-year survival rates did not significantly differ between the operation alone group and the postoperative prophylactic radiotherapy group. For patients without lymph node metastasis, the 1-, 3-, and 5-year survival rates were 94.34%, 51.55%, and 34.41%, respectively, in the postoperative radiotherapy group, significantly higher than those in the operation alone group (63.08%, 23.30% and 4.36%; χ(2) = 15.99, P < 0.01). CONCLUSIONS: The independent prognostic factors of esophageal cancer patients after radical resection include the operation mode, intra-operative findings of the extent of tumor invasion, pathological T stage, the number of lymph node metastasis and the number of regions of lymph node metastasis. Postoperative prophylactic radiotherapy is beneficial for esophageal cancer patients with lymph node metastasis.


Subject(s)
Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Esophageal Neoplasms/pathology , Esophageal Neoplasms/surgery , Esophagectomy/methods , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/radiotherapy , Carcinoma, Small Cell/surgery , Carcinoma, Squamous Cell/radiotherapy , Esophageal Neoplasms/radiotherapy , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Postoperative Care , Proportional Hazards Models , Radiotherapy, Adjuvant , Retrospective Studies , Survival Rate
17.
Front Surg ; 9: 959568, 2022.
Article in English | MEDLINE | ID: mdl-36117831

ABSTRACT

Purpose: The prognostic effect of postoperative radiotherapy (PORT) on pathological T3N0M0 (pT3N0M0) esophageal squamous cell carcinoma (ESCC) remains inconclusive. This study aimed to retrospectively investigate patterns of failure and whether PORT after R0 resection improves survival in patients with pT3N0M0 ESCC, compared with surgery alone. Patients and methods: The clinical data of 256 patients with pT3N0M0 ESCC from January 2007 to December 2010 were retrospectively reviewed. The included patients were classified into two groups: the surgery-plus-postoperative radiotherapy group (S + R) and the surgery-alone group (S). Propensity score matching (PSM) was used to create comparable groups that were balanced across several covariates (n = 71 in each group). Statistical analyses were performed using the Kaplan-Meier method and Chi-squared test. Results: In the study cohort, the 5- and 10-year overall survival (OS) rates in the S + R group were 53.4% and 38.4%, and those in the S group were 50.3%, 40.9% (p = 0.810), respectively. The 5- and 10-year disease-free survival (DFS) rates in the S + R group were 47.9% and 32.9%, and those in the S group were 43.2%, 24.0% (p = 0.056), respectively. The results were coincident in the matched samples (p = 0.883, 0.081) after PSM. Subgroup analysis showed that patients with upper thoracic lesions in the S + R group had significantly higher OS than patients in the S group (p = 0.013), in addition, patients with upper and middle thoracic lesions in the S + R group had significantly higher DFS than patients in the S group (p = 0.018, 0.049). The results were also confirmed in the matched samples after PSM. The locoregional recurrence between the two groups were significantly different before and after PSM (p = 0.009, 0.002). The locoregional control rate (LCR) in the S + R group was significantly higher than that in the S group before and after PSM (p = 0.015, 0.008). Conclusion: Postoperative radiotherapy may be associated with a survival benefit for patients with pT3N0M0 upper thoracic ESCC. A multicenter, randomized phase III clinical trial is required to confirm the results of this study.

18.
ACS Omega ; 7(42): 37564-37571, 2022 Oct 25.
Article in English | MEDLINE | ID: mdl-36312401

ABSTRACT

Biomass-derived activated carbon is a widely used electrode material for supercapacitors. One of the keys to preparing high-performance activated carbon is the selection of appropriate precursors. Daylily is a common edible herb and is widely planted in Asia. It is rich in nitrogen and phosphorus, so it can be used as a precursor of heteroatom-doped activated carbon. Herein, a daylily-derived porous carbon with a large specific surface area and high content of heteroatoms has been successfully prepared by a simple carbonization method. The as-prepared carbon materials showed a remarkable specific capacitance of 299.1 F/g at 0.5 A/g and excellent cycling stability of 99.6% after 4000 cycles at a current density of 1 A/g. Moreover, the assembled symmetric supercapacitor showed a high energy density of 21.6 Wh/kg at a power density of 598.2 W/kg in 6 M KOH electrolyte. These results demonstrate that the daylily-derived porous carbon is an excellent material for high-performance supercapacitors.

19.
Front Surg ; 9: 905678, 2022.
Article in English | MEDLINE | ID: mdl-35677748

ABSTRACT

Objective: To analyze and compare the efficacy and safety of simultaneous integrated boost intensity-modulation radiation therapy (SIB-IMRT) combined with systematic and standardized management for esophageal cancer. Methods: From January 2012 to January 2019, 200 patients with esophageal cancer who received radical chemoradiotherapy in our hospital were treated with lymphatic drainage area radiation prevention combined with systematic and standardized management. According to difference in radiotherapy methods, the patients were divided into local lesion 92 patients treated with simultaneous integrated boost intensity-modulation radiation therapy (SIB-IMRT) combined with systematic standardized management (SIB-IMRT group), and late course boost intensity-modulation radiation therapy (LCB-IMRT) combined with systematic standardized management 108 patients (LCB-IMRT group). The short-term eficacy of the two groups were compared. The dose volume parameters of the organ in danger are evaluated based on the dose volume histogram. The related adverse reactions during chemoradiotherapy were compared between two groups. The local control rate and survival rate were compared between the two groups. Results: The recent total effective rates of rats in the SIB-IMRT group and LCB-IMRT group were 95.65% and 90.74%, respectively, and there was no significant difference between the two groups (p > 0.05). The mean doses to left and right lung, heart and spinal cord in the SIB-IMRT group were significantly lower than that in the LCB-IMRT group (p < 0.05). There was no significant difference in the incidence of adverse reactions such as radiation esophagitis, radiation pneumonitis, radiation tracheitis, gastrointestinal reaction and bone marrow suppression between the SIB-IMRT group and LCB-IMRT groups (p > 0.05). The one-year and three-year overall survival rates in the SIB-IMRT group and LCB-IMRT groups were 82.61%, 42.39% and 77.78%, 34.26%, respectively, and the median survival times were 38 and 29 months, respectively. The local control rates in the SIB-IMRT group and LCB-IMRT group in one and three years were 84.78%, 56.52% and 75.93%, 41.67%, respectively. The 3-year local control rate in the SIB-IMRT group was higher than that in the LCB-IMRT group (p < 0.05), but there was no significant difference in the 1-and 3-year overall survival rates between the two groups (p > 0.05). Conclusion: SIB-IMRT combined with systematic and standardized management in the treatment of esophageal cancer can reduce the amount of some organs at risk and improve the local control rate of the lesion.

20.
Anticancer Agents Med Chem ; 22(3): 596-602, 2022.
Article in English | MEDLINE | ID: mdl-33797387

ABSTRACT

BACKGROUND: Papillary Thyroid Carcinoma (PTC) represents the most common thyroid cancer. Until recently, treatment options for PTC patients are limited. Nilotinib is the second-generation tyrosine kinase inhibitor, and has been widely used in the treatment of Chronic Myeloid Leukemia (CML). OBJECTIVES: We aimed to explore whether nilotinib is effective for the suppression PTC cancer progression and the underlying mechanisms. METHODS: In this study, the three human PTC cell lines (KTC-1, BCPAP, and TPC1) were used to verify the effects of nilotinib on cell growth. The half maximal inhibitory concentration (IC50) was calculated according to the growth curve post nilotinib treatment at different concentrations. Cell counting kit-8 and colony formation analysis were used to monitor cell growth after nilotinib treatment. Cell apoptosis and autophagy related proteins and phosphorylation of PI3K/Akt/mTOR were detected by Western blotting analysis. RESULTS: Nilotinib treatment could effectively inhibit PTC cell growth, which was accompanied by an increase in apoptosis and induction of autophagy. Mechanistically, nilotinib treatment repressed the phosphorylation of the PI3K/Akt/mTOR pathway. CONCLUSION: Collectively, our results demonstrated that nilotinib may display anti-tumor effect against PTC via inhibiting PI3K/Akt/mTOR pathway and inducing apoptosis and autophagy.


Subject(s)
Antineoplastic Agents/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrimidines/pharmacology , Thyroid Cancer, Papillary/drug therapy , Thyroid Neoplasms/drug therapy , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinase Inhibitors/chemistry , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/metabolism , Pyrimidines/chemistry , Structure-Activity Relationship , TOR Serine-Threonine Kinases/antagonists & inhibitors , TOR Serine-Threonine Kinases/metabolism , Thyroid Cancer, Papillary/metabolism , Thyroid Cancer, Papillary/pathology , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL